This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Pharmaceutical Technology has listed some of the top API biologics companies in contract marketing based on our intel, insights and decades-long experience in the sector. The download contains detailed information on the providers and their services and solutions, alongside contact details to aid your purchasing or hiring decision.
The companies offer various solid dose products and services including, but not limited to, formulation and analytical development, manufacturing capabilities, technology transfer and scale-up, quality and regulatory support, commercial manufacturing, packaging, and warehousing.
In many cases, pharmacompanies select a contract development and manufacturing organisation (CDMO) to develop products versus doing the work themselves for reasons related to cost, convenience, and capacity. In one specific case, Cambrex developed a PDF containing two APIs in suspension in an 80/20 ratio. Faster to market.
A renowned company offers PCD pharma franchise opportunities in diabetic and cardiac medicines. There is a wide scope of these medicines that include tablets, containers, syrups, and soft gels. A renowned company searches for committed experts that are interested in doing fruitful business in this niche.
Q: What is the typical time period between the submission of the briefing package and the pre-IND meeting? A: The FDA’s guidance document indicates the briefing package is submitted four weeks before the meeting. The sponsor-initiated IND is conducted by a pharmacompany seeking commercial approval.
Russia is an already insular country and its worldview has tended to be self-contained, but this has hardened in the face of recent sanctions and counter-sanctions imposed during the war with Ukraine. Several global pharmacompanies have already withdrawn their support following Russia’s invasion of Ukraine, which began on 24 February.
Unfortunately, I learned the hard way that the “Big Pharma” companies don’t care about their patients. It contains something called boswellic acids that gives it these amazing properties. Tea tree contains a high concentration of Terpinin-4-ol, an anti-inflammatory compound. It’s all about the bottom line, at any cost.
With the new version of EU GMP Annex 1 coming into effect on 25 August this year, big changes to the way the pharmaceutical industry approaches container closure integrity testing (CCIT) are in motion. In addition, 100% testing is now required for fusion-sealed containers such as ampoules and IV bags.
A vitally important assay used across various stages of drug development and manufacturing, container closure integrity testing (CCIT) involves evaluating packaging systems to determine their ability to protect the stability and sterility of pharmaceutical products. The evolution of CCIT. Many test methods have thus been developed.
SUMMARY: Large-cap pharmacompanies are trading higher in the morning hours after White House unveiled a framework for a deal on President Biden’s social spending package on Thursday leaving out a key provision that allowed Medicare to negotiate lower prescription drug prices. Congratulations big pharma.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content